Noble Financial Capital Markets Appoints Healthcare Scientific

Noble Financial Capital Markets Appoints Healthcare Scientific
Advisory Board 
BOCA RATON, FL -- (Marketwire) -- 12/04/12 --  Noble Financial
Capital Markets (Noble) announced today that it has established a
scientific advisory board (SAB). Jules Musing, a Large Pharma veteran
who will chair the Board, is excited about the developmental
prospects for the SAB. "Establishment of this Board represents a bold
strategic initiative for Noble," said Musing. "Not only are
innovations in the Healthcare sector moving forward at a blistering
speed, the regulatory and scientific process has become exceedingly
complex and it takes this kind of commitment to establish credibility
with the various constituents," he said.  
According to Noble's President, Nico P. Pronk, the SAB is a logical
extension of the services provided to its investment banking,
merchant banking, and corporate advisory clients. "These are seasoned
professionals with extensive experience in cutting edge academic and
clinical research, as well as Big Pharma business development,
licensing, M&A, IP and R&D pipeline strategy," said Pronk. "We are
honored to partner with them, and believe that their breadth of
experience and network will be of great value to our clients and the
Noble healthcare team." 
Noble's Scientific Board of Advisors is comprised of the following
professionals: 
Kapil Dhingra, M.D. 
 Dr. Kapil Dhingra was formerly Vice President
and the Head of the Oncology Disease Biology Leadership Team with
Hoffman-La Roche. He is an experienced oncologist, drug developer and
pharmaceutical executive with a proven track record in academic
research, patient care and drug development from initiation through
phase IV. Prior to joining the industry, he had a successful academic
career at M.D. Anderson Cancer Center. He has been a member of the
Board of Directors of Micromet and Biovex. Presently, he serves on
the Boards of Algeta, Exosome Diagnostics and YM Biosciences and is
an advisor to a number of biotechnology and pharmaceutical companies. 
Victor Hartmann, M.D.
 Dr. Victor Hartmann was formerly the head of
Corporate and Strategic Development at Vertex Pharmaceuticals
(NASDAQ: VRTX), head of the Business Development and Licensing and
head of Global Project Management a
t Novartis Pharma AG, head of
Clinical Research and Development at Sandoz Pharmaceutical
Corporation and head of Medical Affairs at Boehringer Ingelheim. Dr.
Hartmann is currently a consultant to biotechnology and
pharmaceutical companies advising them on business development
transactions, strategic planning and process reengineering relevant
to establishing alliances. 
Robert Karr, M.D. 
 Dr. Karr formerly served as President of Idera
Pharmaceuticals (NASDAQ: IDRA) and continues to serve on the Board.
He has held progressively senior positions, primarily in strategic
roles for Pfizer and Warner-Lambert. Dr. Karr also served as
Associate Clinical Professor of Medicine at the Washington University
School of Medicine. Since obtaining his M.D. from the University of
Texas Medical Branch in 1975, Dr. Karr has extensive experience
across the drug discovery and development process (discovery,
pre-clinical, and clinical), as well as experience in fundraising and
partnerships with pharmaceutical companies. 
Michael Keller, J.D.
 Mr. Keller is a partner with the law firm
Roetzel & Andress. Throughout his 20-plus legal career, Mr. Keller
has focused on patent prosecution, counseling and licensing of
therapeutic, diagnostic, pharmaceutical and medical device products.
He has negotiated complex product acquisition agreements with
companies such as Bristol Myers Squibb, Glaxo Wellcome, P&G and
Pfizer, and has evaluated more than 600 product acquisition
candidates. 
Jules A. Musing, Chairman 
 Mr. Musing is the former Global Head of
Biotechnology Licensing and Business Development and has been
responsible for global Drug Licensing at Johnson & Johnson (NYSE:
JNJ). In that position he negotiated and signed several multi-million
dollar deals with medium and large pharmaceutical and biotechnology
companies on a worldwide basis. He has more than 36 years' experience
in the biotechnology and pharmaceutical industry and has been
President and Managing Director of Johnson & Johnson Companies in the
US and Europe, President of Ares Serono in the US and Executive Vice
President for Ares Serono companies in North and Latin America. Mr.
Musing has been on the Board of Johnson & Johnson Companies in
Germany, France, Italy and the UK, and has been a Member of the
Management Board of Ortho Biotech, (a J&J Biotechnology Company) in
the US and Europe. He has been a member of the Board of several
companies and presently serves on the Board of Delphi Digital, Inc.,
and is an advisor to a number of biotechnology and pharmaceutical
companies. 
Staf Van Reet, Ph.D.
 Dr. Van Reet is a former executive at Johnson &
Johnson who lead corporate venturing activities in Europe and was a
member of the J&J Pharma Group Operating Committee. He has been
responsible for all worldwide R&D activities of the Janssen Group of
Companies as President of the Janssen Research Foundation and has
been Managing Director of Janssen Pharmaceutica N.V. and Janssen
Biotech. Dr. Van Reet is an accomplished Belgian scientist and
businessman, who is currently the Managing Director of Viziphar
Biosciences and on the Boards of several companies including,
Actogenix, Okapi Sciences, Octoplus, Thrombogenix, Biocartis and
Therasolve.  
Noble Financial Capital Markets, established in 1984, is an equity
research-driven, investment banking / corporate advisory boutique
with concentration in the healthcare, technology, media,
telecommunications and business services sectors. 
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2171996 
Mark Pinvidic
561 994 5742 
mpinvidic@noblefcm.com 
 
 
Press spacebar to pause and continue. Press esc to stop.